GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$62M
▼ -23.9% YoY
Op. Margin
–
ROIC
-20.85%
▼ -1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$52M
▼ -3.2% YoY
Op. Cash Flow (TTM)
-$52M
▼ -3.0% YoY
Net Debt
-$280M
Net Cash Position
Cash & Equiv.
$281M
Continue Research
Peers
Biotechnology · Pick stocks to compare with GHRS
Held by ETFs
GHRS is in 7 US ETFs. The largest of them, with GHRS's weight in each:
iShares Biotechnology ETFIBB0.07%of the fund
ProShares Ultra Nasdaq BiotechnologyBIB0.07%of the fund
Invesco Nasdaq Biotechnology ETFIBBQ0.12%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.89%of the fund
- PSAdvisorShares Psychedelics ETFPSIL4.31%of the fund
GH Research (GHRS) in three numbers
Questions about GH Research
Is GH Research a high-quality business?
GH Research scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$280M, and its weakest is return on capital at -20.9%. The Quality tab shows every check against its target.
Does GH Research (GHRS) pay a dividend?
No. GH Research (GHRS) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing GHRS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.